Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Nitrendipine
- Accession Number
- DB01054 (APRD00421)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. [PubChem]
- Structure
Structure for DB01054 (Nitrendipine)
- Synonyms
- 1,4-dihydro-2,6-Dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester
- BAY e 5009
- Bayotensin
- Baypress
- Bylotensin
- Deiten
- Nidrel
- Nitrendipino
- Nitrendipinum
- International/Other Brands
- Bayotensin / Baypress / Deiten / Nidrel / Nitrepin / Nitrezic
- Categories
- ACE Inhibitors and Calcium Channel Blockers
- Antiarrhythmic agents
- Antihypertensive Agents
- BSEP/ABCB11 Substrates
- Calcium Channel Blockers
- Calcium Channel Blockers, Dihydropyridine and Nondihydropyridine
- Cardiovascular Agents
- Cardiovascular System
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates (strength unknown)
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 CYP3A7 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Dihydropyridine Derivatives
- Dihydropyridines
- Hypotensive Agents
- Membrane Transport Modulators
- P-glycoprotein/ABCB1 Inhibitors
- Pyridines
- Selective Calcium Channel Blockers With Mainly Vascular Effects
- Vasodilating Agents
- UNII
- 9B627AW319
- CAS number
- 39562-70-4
- Weight
- Average: 360.3612
Monoisotopic: 360.132136382 - Chemical Formula
- C18H20N2O6
- InChI Key
- PVHUJELLJLJGLN-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
- IUPAC Name
- 3-ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- SMILES
- CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
Pharmacology
- Indication
For the treatment of mild to moderate hypertension
- Pharmacodynamics
Nitrendipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nitrendipine is similar to other peripheral vasodilators. Nitrendipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
- Mechanism of action
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nitrendipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Target Actions Organism AVoltage-dependent L-type calcium channel subunit alpha-1C inhibitorHuman AVoltage-dependent calcium channel subunit alpha-2/delta-1 inhibitorHuman AVoltage-dependent L-type calcium channel subunit beta-2 inhibitorHuman AVoltage-dependent calcium channel gamma-1 subunit inhibitorHuman AVoltage-dependent L-type calcium channel subunit alpha-1D inhibitorHuman AVoltage-dependent L-type calcium channel subunit alpha-1S inhibitorHuman UVoltage-dependent calcium channel subunit alpha-2/delta-2 inhibitorHuman UVoltage-dependent T-type calcium channel subunit alpha-1H inhibitorHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
> 99%
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Nitrendipine Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Abafungin The therapeutic efficacy of Abafungin can be increased when used in combination with Nitrendipine. Investigational Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Nitrendipine. Approved, Investigational Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Nitrendipine. Approved, Investigational Aceclofenac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Aceclofenac. Approved, Investigational Acemetacin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Acepromazine The risk or severity of hypotension can be increased when Acepromazine is combined with Nitrendipine. Approved, Vet Approved Acetylsalicylic acid The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Acetylsalicylic acid. Approved, Vet Approved Afatinib The serum concentration of Afatinib can be increased when it is combined with Nitrendipine. Approved Albaconazole The therapeutic efficacy of Albaconazole can be increased when used in combination with Nitrendipine. Investigational Alclofenac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Alclofenac. Approved, Withdrawn Alcuronium Nitrendipine may increase the neuromuscular blocking activities of Alcuronium. Experimental Aldesleukin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Aldesleukin. Approved Aldosterone The serum concentration of Aldosterone can be increased when it is combined with Nitrendipine. Experimental, Investigational Alfuzosin Alfuzosin may increase the hypotensive activities of Nitrendipine. Approved, Investigational Aliskiren Nitrendipine may increase the hypotensive activities of Aliskiren. Approved, Investigational Alitretinoin The serum concentration of Alitretinoin can be increased when it is combined with Nitrendipine. Approved, Investigational Alminoprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Alminoprofen. Experimental Alprenolol Nitrendipine may increase the hypotensive activities of Alprenolol. Approved, Withdrawn Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Nitrendipine. Approved, Investigational Amifostine Nitrendipine may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Nitrendipine is combined with Amiloride. Approved Aminophenazone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Aminophenazone. Approved, Withdrawn Amiodarone The risk or severity of adverse effects can be increased when Amiodarone is combined with Nitrendipine. Approved, Investigational Amitriptyline The risk or severity of hypotension can be increased when Amitriptyline is combined with Nitrendipine. Approved Amlodipine Amlodipine may increase the hypotensive activities of Nitrendipine. Approved Amobarbital Amobarbital may increase the hypotensive activities of Nitrendipine. Approved, Illicit Amoxapine The risk or severity of hypotension can be increased when Amoxapine is combined with Nitrendipine. Approved Amphotericin B Nitrendipine may decrease the nephrotoxic activities of Amphotericin B. Approved, Investigational Amprenavir The serum concentration of Amprenavir can be increased when it is combined with Nitrendipine. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Nitrendipine is combined with Amyl Nitrite. Approved Antipyrine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Antipyrine. Approved, Investigational Antrafenine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Antrafenine. Approved Apalutamide The serum concentration of Nitrendipine can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban The serum concentration of Apixaban can be increased when it is combined with Nitrendipine. Approved Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrendipine. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Apraclonidine. Approved Aprepitant The serum concentration of Nitrendipine can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole Aripiprazole may increase the hypotensive activities of Nitrendipine. Approved, Investigational Aripiprazole lauroxil The risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Nitrendipine. Approved, Investigational Arotinolol The risk or severity of hypotension can be increased when Arotinolol is combined with Nitrendipine. Investigational Arsenic trioxide The serum concentration of Arsenic trioxide can be increased when it is combined with Nitrendipine. Approved, Investigational Ascorbic acid The serum concentration of Ascorbic acid can be increased when it is combined with Nitrendipine. Approved, Nutraceutical Asenapine The risk or severity of hypotension can be increased when Asenapine is combined with Nitrendipine. Approved Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Nitrendipine. Approved, Investigational, Withdrawn Atazanavir The metabolism of Nitrendipine can be decreased when combined with Atazanavir. Approved, Investigational Atenolol Atenolol may increase the hypotensive activities of Nitrendipine. Approved Atorvastatin The serum concentration of Atorvastatin can be increased when it is combined with Nitrendipine. Approved Atracurium Nitrendipine may increase the neuromuscular blocking activities of Atracurium. Approved, Experimental, Investigational Atracurium besylate Nitrendipine may increase the neuromuscular blocking activities of Atracurium besylate. Approved Avanafil Avanafil may increase the antihypertensive activities of Nitrendipine. Approved Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Nitrendipine. Approved, Investigational Axitinib The serum concentration of Axitinib can be increased when it is combined with Nitrendipine. Approved, Investigational Azapropazone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Azapropazone. Withdrawn Azilsartan medoxomil The risk or severity of adverse effects can be increased when Nitrendipine is combined with Azilsartan medoxomil. Approved, Investigational Balsalazide The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Balsalazide. Approved, Investigational Barbexaclone Barbexaclone may increase the hypotensive activities of Nitrendipine. Experimental Barbital Barbital may increase the hypotensive activities of Nitrendipine. Illicit Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Nitrendipine. Approved, Investigational Barnidipine Nitrendipine may increase the antihypertensive activities of Barnidipine. Approved Belinostat The serum concentration of Belinostat can be increased when it is combined with Nitrendipine. Approved, Investigational Benazepril Benazepril may increase the hypotensive activities of Nitrendipine. Approved, Investigational Benazeprilat Nitrendipine may increase the hypotensive activities of Benazeprilat. Experimental Bendazac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Bendazac. Experimental Bendroflumethiazide Bendroflumethiazide may increase the hypotensive activities of Nitrendipine. Approved Benmoxin Benmoxin may increase the hypotensive activities of Nitrendipine. Withdrawn Benorilate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Benorilate. Experimental Benoxaprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Benoxaprofen. Withdrawn Benzydamine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Benzydamine. Approved Bepridil Nitrendipine may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betamethasone The serum concentration of Betamethasone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Betaxolol Betaxolol may increase the hypotensive activities of Nitrendipine. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Nitrendipine. Approved Bevantolol The risk or severity of hypotension can be increased when Bevantolol is combined with Nitrendipine. Approved Bietaserpine Bietaserpine may increase the hypotensive activities of Nitrendipine. Experimental Bifonazole The therapeutic efficacy of Bifonazole can be increased when used in combination with Nitrendipine. Approved, Investigational Bimatoprost Bimatoprost may increase the hypotensive activities of Nitrendipine. Approved, Investigational Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Nitrendipine. Approved Bisoprolol Bisoprolol may increase the hypotensive activities of Nitrendipine. Approved Bisoxatin The therapeutic efficacy of Bisoxatin can be decreased when used in combination with Nitrendipine. Approved Boceprevir The metabolism of Nitrendipine can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Nitrendipine. Approved, Investigational Bosentan The serum concentration of Nitrendipine can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Nitrendipine. Approved BQ-123 Nitrendipine may increase the hypotensive activities of BQ-123. Investigational Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine. Approved, Investigational Bretylium Nitrendipine may increase the hypotensive activities of Bretylium. Approved Brexpiprazole The risk or severity of hypotension can be increased when Brexpiprazole is combined with Nitrendipine. Approved, Investigational Bromfenac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Bromfenac. Approved Bromocriptine The risk or severity of hypotension can be increased when Bromocriptine is combined with Nitrendipine. Approved, Investigational Bromperidol The serum concentration of Bromperidol can be increased when it is combined with Nitrendipine. Approved, Investigational Bucindolol The risk or severity of hypotension can be increased when Bucindolol is combined with Nitrendipine. Investigational Bufexamac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Bufexamac. Approved, Experimental Bumadizone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Bumadizone. Experimental Bumetanide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Bumetanide. Approved Bunazosin The risk or severity of hypotension can be increased when Bunazosin is combined with Nitrendipine. Investigational Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrendipine. Approved, Investigational Bupranolol Nitrendipine may increase the hypotensive activities of Bupranolol. Approved Butoconazole The therapeutic efficacy of Butoconazole can be increased when used in combination with Nitrendipine. Approved Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Nitrendipine. Approved Cadralazine Cadralazine may increase the hypotensive activities of Nitrendipine. Experimental Calcium Acetate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Acetate. Approved, Investigational Calcium Carbonate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Carbonate. Approved, Investigational Calcium Chloride The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Chloride. Approved Calcium Citrate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Citrate. Approved Calcium glubionate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium glubionate. Approved Calcium Gluceptate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Gluceptate. Approved Calcium gluconate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium gluconate. Approved, Vet Approved Calcium lactate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate. Approved, Investigational, Vet Approved Calcium lactate gluconate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate gluconate. Experimental Calcium levulinate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium levulinate. Approved, Experimental Calcium pangamate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium pangamate. Experimental Calcium Phosphate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Phosphate. Approved Camptothecin The serum concentration of Camptothecin can be increased when it is combined with Nitrendipine. Experimental Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Nitrendipine. Approved Candesartan Nitrendipine may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil Candesartan cilexetil may increase the hypotensive activities of Nitrendipine. Approved Candoxatril Candoxatril may increase the hypotensive activities of Nitrendipine. Experimental Captopril Nitrendipine may increase the hypotensive activities of Captopril. Approved Carbamazepine The metabolism of Nitrendipine can be increased when combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Carbaspirin calcium. Experimental, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Nitrendipine. Approved, Investigational Carboxymethylcellulose The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nitrendipine. Approved, Investigational Carfilzomib The serum concentration of Carfilzomib can be increased when it is combined with Nitrendipine. Approved, Investigational Caroxazone Caroxazone may increase the hypotensive activities of Nitrendipine. Withdrawn Carprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Carprofen. Approved, Vet Approved, Withdrawn Carteolol Nitrendipine may increase the hypotensive activities of Carteolol. Approved Carvedilol The risk or severity of hypotension can be increased when Carvedilol is combined with Nitrendipine. Approved, Investigational Castor oil The therapeutic efficacy of Castor oil can be decreased when used in combination with Nitrendipine. Approved, Investigational, Nutraceutical, Vet Approved Celecoxib The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Celecoxib. Approved, Investigational Celiprolol The serum concentration of Celiprolol can be increased when it is combined with Nitrendipine. Approved, Investigational Ceritinib The serum concentration of Nitrendipine can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Nitrendipine. Approved, Withdrawn Cerliponase alfa The serum concentration of Cerliponase alfa can be increased when it is combined with Nitrendipine. Approved, Investigational Chlorambucil The serum concentration of Chlorambucil can be increased when it is combined with Nitrendipine. Approved Chloroquine The serum concentration of Chloroquine can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Chlorothiazide Chlorothiazide may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Chlorpromazine The risk or severity of hypotension can be increased when Chlorpromazine is combined with Nitrendipine. Approved, Investigational, Vet Approved Chlorthalidone Chlorthalidone may increase the hypotensive activities of Nitrendipine. Approved Choline magnesium trisalicylate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Choline magnesium trisalicylate. Approved Cicletanine Nitrendipine may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Nitrendipine may increase the hypotensive activities of Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitrendipine. Approved, Investigational Cimetidine The serum concentration of Nitrendipine can be increased when it is combined with Cimetidine. Approved, Investigational Cimicoxib The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Cimicoxib. Investigational Ciprofloxacin The serum concentration of Ciprofloxacin can be increased when it is combined with Nitrendipine. Approved, Investigational Cisatracurium Nitrendipine may increase the neuromuscular blocking activities of Cisatracurium. Approved Cisplatin The serum concentration of Cisplatin can be increased when it is combined with Nitrendipine. Approved Citalopram The serum concentration of Citalopram can be increased when it is combined with Nitrendipine. Approved Clarithromycin The metabolism of Nitrendipine can be decreased when combined with Clarithromycin. Approved Clevidipine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Clevidipine. Approved, Investigational Clobazam The serum concentration of Clobazam can be increased when it is combined with Nitrendipine. Approved, Illicit Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrendipine. Approved, Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Nitrendipine. Approved, Investigational, Vet Approved Clonidine The serum concentration of Clonidine can be increased when it is combined with Nitrendipine. Approved Clonixin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Clonixin. Approved Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nitrendipine. Approved Cloranolol Nitrendipine may increase the hypotensive activities of Cloranolol. Experimental Clotrimazole The metabolism of Nitrendipine can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of hypotension can be increased when Clozapine is combined with Nitrendipine. Approved Cobicistat The metabolism of Nitrendipine can be decreased when combined with Cobicistat. Approved Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Nitrendipine. Approved, Investigational Colchicine The serum concentration of Colchicine can be increased when it is combined with Nitrendipine. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Nitrendipine. Approved, Investigational Conjugated estrogens The serum concentration of Conjugated estrogens can be increased when it is combined with Nitrendipine. Approved Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Nitrendipine. Approved, Investigational Crizotinib The serum concentration of Crizotinib can be increased when it is combined with Nitrendipine. Approved Cryptenamine Cryptenamine may increase the hypotensive activities of Nitrendipine. Approved Curcumin The metabolism of Nitrendipine can be decreased when combined with Curcumin. Approved, Investigational Cyclopenthiazide Nitrendipine may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Cyclothiazide Cyclothiazide may increase the hypotensive activities of Nitrendipine. Approved Cytarabine The serum concentration of Cytarabine can be increased when it is combined with Nitrendipine. Approved, Investigational Dabigatran etexilate The serum concentration of Dabigatran etexilate can be increased when it is combined with Nitrendipine. Approved Dabrafenib The serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib. Approved, Investigational Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Nitrendipine. Approved, Investigational Danazol The metabolism of Nitrendipine can be decreased when combined with Danazol. Approved Danthron The therapeutic efficacy of Danthron can be decreased when used in combination with Nitrendipine. Approved, Investigational, Withdrawn Dapagliflozin The serum concentration of Dapagliflozin can be increased when it is combined with Nitrendipine. Approved Dapiprazole The risk or severity of hypotension can be increased when Dapiprazole is combined with Nitrendipine. Approved Darunavir The metabolism of Nitrendipine can be decreased when combined with Darunavir. Approved Dasabuvir The serum concentration of Dasabuvir can be increased when it is combined with Nitrendipine. Approved Daunorubicin The serum concentration of Daunorubicin can be increased when it is combined with Nitrendipine. Approved Debrisoquin The serum concentration of Debrisoquin can be increased when it is combined with Nitrendipine. Approved, Investigational Deferasirox The serum concentration of Nitrendipine can be decreased when it is combined with Deferasirox. Approved, Investigational Delapril Nitrendipine may increase the hypotensive activities of Delapril. Investigational Delavirdine The metabolism of Nitrendipine can be decreased when combined with Delavirdine. Approved Deserpidine Nitrendipine may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Nitrendipine. Approved Dexamethasone The serum concentration of Dexamethasone can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Dexibuprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Dexibuprofen. Approved, Investigational Dexketoprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Dexketoprofen. Approved, Investigational Dexmedetomidine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dexmedetomidine. Approved, Vet Approved Dexniguldipine Nitrendipine may increase the hypotensive activities of Dexniguldipine. Experimental Diazepam The serum concentration of Diazepam can be increased when it is combined with Nitrendipine. Approved, Illicit, Investigational, Vet Approved Diazoxide Diazoxide may increase the hypotensive activities of Nitrendipine. Approved Diclofenac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Diclofenac. Approved, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Diclofenamide. Approved, Investigational Diethylnorspermine Nitrendipine may increase the hypotensive activities of Diethylnorspermine. Investigational Diethylstilbestrol The serum concentration of Diethylstilbestrol can be increased when it is combined with Nitrendipine. Approved, Investigational Difenpiramide The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Difenpiramide. Experimental Diflunisal The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Diflunisal. Approved, Investigational Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Nitrendipine. Approved, Investigational Digoxin The serum concentration of Digoxin can be increased when it is combined with Nitrendipine. Approved Dihydralazine Dihydralazine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Dihydroergotamine The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Nitrendipine. Approved, Investigational Diltiazem The metabolism of Nitrendipine can be decreased when combined with Diltiazem. Approved, Investigational Dinutuximab The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dinutuximab. Approved, Investigational Dipyridamole Dipyridamole may increase the antihypertensive activities of Nitrendipine. Approved Docetaxel The serum concentration of Docetaxel can be increased when it is combined with Nitrendipine. Approved, Investigational Docusate The therapeutic efficacy of Docusate can be decreased when used in combination with Nitrendipine. Approved Dolutegravir The serum concentration of Dolutegravir can be increased when it is combined with Nitrendipine. Approved Domperidone The serum concentration of Domperidone can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Dorzolamide Dorzolamide may increase the hypotensive activities of Nitrendipine. Approved Doxacurium Nitrendipine may increase the neuromuscular blocking activities of Doxacurium. Approved Doxazosin The risk or severity of hypotension can be increased when Doxazosin is combined with Nitrendipine. Approved Doxepin The risk or severity of hypotension can be increased when Doxepin is combined with Nitrendipine. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Nitrendipine. Approved, Investigational Doxycycline The metabolism of Nitrendipine can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The risk or severity of hypotension can be increased when Dronedarone is combined with Nitrendipine. Approved Droperidol The risk or severity of hypotension can be increased when Droperidol is combined with Nitrendipine. Approved, Vet Approved Droxicam The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Droxicam. Withdrawn Duloxetine Nitrendipine may increase the orthostatic hypotensive activities of Duloxetine. Approved Econazole The therapeutic efficacy of Econazole can be increased when used in combination with Nitrendipine. Approved Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Nitrendipine. Approved Efavirenz The serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz. Approved, Investigational Efinaconazole The therapeutic efficacy of Efinaconazole can be increased when used in combination with Nitrendipine. Approved Efonidipine Nitrendipine may increase the hypotensive activities of Efonidipine. Approved, Investigational Elagolix The serum concentration of Elagolix can be increased when it is combined with Nitrendipine. Approved, Investigational Elbasvir The serum concentration of Elbasvir can be increased when it is combined with Nitrendipine. Approved Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Nitrendipine. Approved, Investigational Empagliflozin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Empagliflozin. Approved Enalapril Enalapril may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Enalaprilat Nitrendipine may increase the hypotensive activities of Enalaprilat. Approved Endralazine Endralazine may increase the hypotensive activities of Nitrendipine. Experimental Enzalutamide The serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide. Approved Epanolol Nitrendipine may increase the hypotensive activities of Epanolol. Experimental Epinastine The serum concentration of Epinastine can be increased when it is combined with Nitrendipine. Approved, Investigational Epirizole The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Epirizole. Approved Eplerenone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Eplerenone. Approved Epoprostenol Epoprostenol may increase the hypotensive activities of Nitrendipine. Approved Eprosartan Eprosartan may increase the hypotensive activities of Nitrendipine. Approved Ergotamine The risk or severity of hypotension can be increased when Ergotamine is combined with Nitrendipine. Approved Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Nitrendipine. Approved, Investigational Ertugliflozin The serum concentration of Ertugliflozin can be increased when it is combined with Nitrendipine. Approved, Investigational Erythromycin The serum concentration of Erythromycin can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Esatenolol Nitrendipine may increase the hypotensive activities of Esatenolol. Experimental Esmolol Nitrendipine may increase the hypotensive activities of Esmolol. Approved Estradiol The serum concentration of Estradiol can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Estradiol acetate The serum concentration of Estradiol acetate can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Estradiol benzoate The serum concentration of Estradiol benzoate can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of Estradiol cypionate can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Estradiol dienanthate The serum concentration of Estradiol dienanthate can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of Estradiol valerate can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Estriol The serum concentration of Estriol can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Estrone The serum concentration of Estrone can be increased when it is combined with Nitrendipine. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Nitrendipine is combined with Etacrynic acid. Approved, Investigational Ethenzamide The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ethenzamide. Experimental Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be increased when it is combined with Nitrendipine. Approved Etodolac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Etodolac. Approved, Investigational, Vet Approved Etofenamate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Etofenamate. Approved, Investigational Etoposide The serum concentration of Etoposide can be increased when it is combined with Nitrendipine. Approved Etoricoxib The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Etoricoxib. Approved, Investigational Etravirine The serum concentration of Nitrendipine can be decreased when it is combined with Etravirine. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Nitrendipine. Approved Ezetimibe The serum concentration of Ezetimibe can be increased when it is combined with Nitrendipine. Approved Felbinac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Felbinac. Experimental Felodipine Felodipine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Fenbufen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Fenbufen. Approved Fenoldopam Fenoldopam may increase the hypotensive activities of Nitrendipine. Approved Fenoprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Fenoprofen. Approved Fentiazac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Fentiazac. Experimental Fenticonazole The therapeutic efficacy of Fenticonazole can be increased when used in combination with Nitrendipine. Experimental Feprazone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Feprazone. Experimental Ferulic acid Nitrendipine may increase the hypotensive activities of Ferulic acid. Experimental Fesoterodine The serum concentration of Fesoterodine can be increased when it is combined with Nitrendipine. Approved Fexofenadine The serum concentration of Fexofenadine can be increased when it is combined with Nitrendipine. Approved, Investigational Fidaxomicin The serum concentration of Fidaxomicin can be increased when it is combined with Nitrendipine. Approved Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Nitrendipine. Approved, Investigational Firocoxib The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Firocoxib. Experimental, Vet Approved Floctafenine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Floctafenine. Approved, Withdrawn Fluciclovine (18F) The serum concentration of Fluciclovine (18F) can be increased when it is combined with Nitrendipine. Approved Fluconazole The metabolism of Nitrendipine can be decreased when combined with Fluconazole. Approved, Investigational Flunixin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Flunixin. Vet Approved Flunoxaprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Flunoxaprofen. Experimental Flupentixol The risk or severity of hypotension can be increased when Flupentixol is combined with Nitrendipine. Approved, Investigational, Withdrawn Flurbiprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Flurbiprofen. Approved, Investigational Fluticasone The serum concentration of Fluticasone can be increased when it is combined with Nitrendipine. Approved, Experimental, Investigational Fluticasone furoate The serum concentration of Fluticasone furoate can be increased when it is combined with Nitrendipine. Approved Fluticasone propionate The serum concentration of Fluticasone propionate can be increased when it is combined with Nitrendipine. Approved Flutrimazole The therapeutic efficacy of Flutrimazole can be increased when used in combination with Nitrendipine. Experimental Fluvoxamine The metabolism of Nitrendipine can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Nitrendipine can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Nitrendipine can be increased when it is combined with Fosaprepitant. Approved Fosinopril Fosinopril may increase the hypotensive activities of Nitrendipine. Approved Fosinoprilat Nitrendipine may increase the hypotensive activities of Fosinoprilat. Experimental Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Nitrendipine. Approved, Investigational Fostamatinib Fostamatinib may increase the antihypertensive activities of Nitrendipine. Approved, Investigational Furazolidone Furazolidone may increase the hypotensive activities of Nitrendipine. Approved, Investigational, Vet Approved Furosemide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Furosemide. Approved, Vet Approved Fusidic Acid The serum concentration of Nitrendipine can be increased when it is combined with Fusidic Acid. Approved, Investigational Gallamine Nitrendipine may increase the neuromuscular blocking activities of Gallamine. Experimental Gallamine Triethiodide Nitrendipine may increase the neuromuscular blocking activities of Gallamine Triethiodide. Approved Gefitinib The serum concentration of Gefitinib can be increased when it is combined with Nitrendipine. Approved, Investigational Glecaprevir The serum concentration of Glecaprevir can be increased when it is combined with Nitrendipine. Approved, Investigational Glycerin The therapeutic efficacy of Glycerin can be decreased when used in combination with Nitrendipine. Approved, Investigational Gramicidin D The serum concentration of Gramicidin D can be increased when it is combined with Nitrendipine. Approved Grazoprevir The serum concentration of Grazoprevir can be increased when it is combined with Nitrendipine. Approved Grepafloxacin The serum concentration of Grepafloxacin can be increased when it is combined with Nitrendipine. Approved, Investigational, Withdrawn Guacetisal The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Guacetisal. Experimental Guanabenz Guanabenz may increase the hypotensive activities of Nitrendipine. Approved, Investigational Guanadrel Guanadrel may increase the hypotensive activities of Nitrendipine. Approved Guanazodine Nitrendipine may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Nitrendipine may increase the hypotensive activities of Guanethidine. Approved Guanfacine Guanfacine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Guanoclor Nitrendipine may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Nitrendipine may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Nitrendipine may increase the hypotensive activities of Guanoxan. Experimental Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Nitrendipine. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Nitrendipine. Experimental Hexamethonium Nitrendipine may increase the hypotensive activities of Hexamethonium. Experimental Hexobarbital Hexobarbital may increase the hypotensive activities of Nitrendipine. Approved Hydracarbazine Hydracarbazine may increase the hypotensive activities of Nitrendipine. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Nitrendipine. Approved Hydrochlorothiazide Hydrochlorothiazide may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Hydrocortisone The serum concentration of Hydrocortisone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Hydroflumethiazide Hydroflumethiazide may increase the hypotensive activities of Nitrendipine. Approved, Investigational Hydroxyurea The serum concentration of Hydroxyurea can be increased when it is combined with Nitrendipine. Approved Ibuprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ibuprofen. Approved Ibuproxam The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ibuproxam. Withdrawn Icosapent The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Icosapent. Approved, Nutraceutical Idelalisib The metabolism of Nitrendipine can be decreased when combined with Idelalisib. Approved Iloperidone The risk or severity of hypotension can be increased when Iloperidone is combined with Nitrendipine. Approved Iloprost Iloprost may increase the hypotensive activities of Nitrendipine. Approved, Investigational Imatinib The serum concentration of Imatinib can be increased when it is combined with Nitrendipine. Approved Imidapril Nitrendipine may increase the hypotensive activities of Imidapril. Investigational Imidazole salicylate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Imidazole salicylate. Experimental Imipramine The risk or severity of hypotension can be increased when Imipramine is combined with Nitrendipine. Approved Indacaterol The serum concentration of Indacaterol can be increased when it is combined with Nitrendipine. Approved Indapamide Indapamide may increase the hypotensive activities of Nitrendipine. Approved Indenolol Nitrendipine may increase the hypotensive activities of Indenolol. Withdrawn Indinavir The metabolism of Nitrendipine can be decreased when combined with Indinavir. Approved Indobufen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Indobufen. Investigational Indomethacin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Indomethacin. Approved, Investigational Indoprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Indoprofen. Withdrawn Indoramin The risk or severity of hypotension can be increased when Indoramin is combined with Nitrendipine. Withdrawn Inotuzumab ozogamicin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Nitrendipine. Approved, Investigational Iproniazid Iproniazid may increase the hypotensive activities of Nitrendipine. Withdrawn Irbesartan Irbesartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Irinotecan The serum concentration of Irinotecan can be increased when it is combined with Nitrendipine. Approved, Investigational Isavuconazole The serum concentration of Nitrendipine can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Nitrendipine can be decreased when combined with Isavuconazonium. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypotensive activities of Nitrendipine. Approved Isoconazole The therapeutic efficacy of Isoconazole can be increased when used in combination with Nitrendipine. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Nitrendipine. Approved, Vet Approved Isoniazid The metabolism of Nitrendipine can be decreased when combined with Isoniazid. Approved, Investigational Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Mononitrate. Approved Isoxicam The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Isoxicam. Withdrawn Isoxsuprine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isoxsuprine. Approved, Withdrawn Isradipine Isradipine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Itraconazole The metabolism of Nitrendipine can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Nitrendipine can be increased when it is combined with Ivacaftor. Approved Ivermectin The serum concentration of Ivermectin can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Ivosidenib The serum concentration of Ivosidenib can be increased when it is combined with Nitrendipine. Approved, Investigational Kebuzone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Kebuzone. Experimental Ketanserin Ketanserin may increase the hypotensive activities of Nitrendipine. Investigational Ketazolam The serum concentration of Ketazolam can be increased when it is combined with Nitrendipine. Approved Ketoconazole The metabolism of Nitrendipine can be decreased when combined with Ketoconazole. Approved, Investigational Ketoprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Ketorolac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ketorolac. Approved Labetalol The risk or severity of hypotension can be increased when Labetalol is combined with Nitrendipine. Approved Lacidipine Nitrendipine may increase the hypotensive activities of Lacidipine. Approved, Investigational Lactitol The therapeutic efficacy of Lactitol can be decreased when used in combination with Nitrendipine. Investigational Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Nitrendipine. Approved Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Nitrendipine. Approved, Investigational Lamotrigine The serum concentration of Lamotrigine can be increased when it is combined with Nitrendipine. Approved, Investigational Lansoprazole The serum concentration of Lansoprazole can be increased when it is combined with Nitrendipine. Approved, Investigational Latanoprost Latanoprost may increase the hypotensive activities of Nitrendipine. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Nitrendipine. Approved Lenalidomide The serum concentration of Lenalidomide can be increased when it is combined with Nitrendipine. Approved Lenvatinib The serum concentration of Lenvatinib can be increased when it is combined with Nitrendipine. Approved, Investigational Lercanidipine Lercanidipine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Letermovir The serum concentration of Letermovir can be increased when it is combined with Nitrendipine. Approved, Investigational Levetiracetam The serum concentration of Levetiracetam can be increased when it is combined with Nitrendipine. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nitrendipine. Approved, Investigational Levodopa Nitrendipine may increase the orthostatic hypotensive activities of Levodopa. Approved Levofloxacin The serum concentration of Levofloxacin can be increased when it is combined with Nitrendipine. Approved, Investigational Levomilnacipran The serum concentration of Levomilnacipran can be increased when it is combined with Nitrendipine. Approved, Investigational Levosimendan The risk or severity of adverse effects can be increased when Levosimendan is combined with Nitrendipine. Approved, Investigational Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Nitrendipine. Approved Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Nitrendipine. Approved Linezolid Linezolid may increase the hypotensive activities of Nitrendipine. Approved, Investigational Linsidomine Nitrendipine may increase the hypotensive activities of Linsidomine. Experimental Lisinopril Lisinopril may increase the hypotensive activities of Nitrendipine. Approved, Investigational Lofexidine Nitrendipine may increase the hypotensive activities of Lofexidine. Approved, Investigational Lonazolac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Lonazolac. Experimental Loperamide The serum concentration of Loperamide can be increased when it is combined with Nitrendipine. Approved Lopinavir The metabolism of Nitrendipine can be decreased when combined with Lopinavir. Approved Lornoxicam The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Lornoxicam. Approved, Investigational Lorpiprazole The serum concentration of Nitrendipine can be increased when it is combined with Lorpiprazole. Approved Losartan The serum concentration of Losartan can be increased when it is combined with Nitrendipine. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Nitrendipine. Approved, Investigational Loxoprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Loxoprofen. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nitrendipine. Approved, Investigational Luliconazole The serum concentration of Nitrendipine can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Nitrendipine can be increased when combined with Lumacaftor. Approved Lumiracoxib The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Lumiracoxib. Approved, Investigational Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Nitrendipine. Approved, Investigational Macitentan Nitrendipine may increase the hypotensive activities of Macitentan. Approved Magnesium carbonate The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Nitrendipine. Approved, Investigational Magnesium citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Nitrendipine. Approved Magnesium hydroxide The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium oxide. Approved Magnesium peroxide The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Nitrendipine. Experimental Magnesium salicylate The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium salicylate. Approved Magnesium sulfate The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine Nitrendipine may increase the hypotensive activities of Manidipine. Approved, Investigational Mannitol The therapeutic efficacy of Mannitol can be decreased when used in combination with Nitrendipine. Approved, Investigational Mebanazine Mebanazine may increase the hypotensive activities of Nitrendipine. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Meclofenamic acid The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Mefenamic acid The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Mefenamic acid. Approved Mefloquine The serum concentration of Mefloquine can be increased when it is combined with Nitrendipine. Approved, Investigational Meloxicam The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Meloxicam. Approved, Vet Approved Melphalan The serum concentration of Melphalan can be increased when it is combined with Nitrendipine. Approved Mesalazine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Mesalazine. Approved Metamizole The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Metamizole. Approved, Investigational, Withdrawn Methazolamide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Methazolamide. Approved Methohexital Methohexital may increase the hypotensive activities of Nitrendipine. Approved Methoserpidine Nitrendipine may increase the hypotensive activities of Methoserpidine. Experimental Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Nitrendipine. Approved Methotrimeprazine The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nitrendipine. Approved, Investigational Methyclothiazide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Methyclothiazide. Approved Methyl cellulose The therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Nitrendipine. Approved Methyldopa Methyldopa may increase the hypotensive activities of Nitrendipine. Approved Methylene blue Methylene blue may increase the hypotensive activities of Nitrendipine. Approved, Investigational Methylphenidate Methylphenidate may decrease the antihypertensive activities of Nitrendipine. Approved, Investigational Methylphenobarbital Methylphenobarbital may increase the hypotensive activities of Nitrendipine. Approved Methylprednisolone The serum concentration of Methylprednisolone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Metipranolol Nitrendipine may increase the hypotensive activities of Metipranolol. Approved Metocurine Nitrendipine may increase the neuromuscular blocking activities of Metocurine. Approved Metocurine Iodide Nitrendipine may increase the neuromuscular blocking activities of Metocurine Iodide. Approved, Withdrawn Metolazone Metolazone may increase the hypotensive activities of Nitrendipine. Approved Metoprolol Metoprolol may increase the hypotensive activities of Nitrendipine. Approved, Investigational Metyrosine Nitrendipine may increase the hypotensive activities of Metyrosine. Approved Mibefradil The metabolism of Nitrendipine can be decreased when combined with Mibefradil. Investigational, Withdrawn Miconazole The metabolism of Nitrendipine can be decreased when combined with Miconazole. Approved, Investigational, Vet Approved Mifepristone The serum concentration of Nitrendipine can be increased when it is combined with Mifepristone. Approved, Investigational Minaprine Minaprine may increase the hypotensive activities of Nitrendipine. Approved Mineral oil The therapeutic efficacy of Mineral oil can be decreased when used in combination with Nitrendipine. Approved, Vet Approved Minoxidil Minoxidil may increase the hypotensive activities of Nitrendipine. Approved, Investigational Mirabegron The serum concentration of Mirabegron can be increased when it is combined with Nitrendipine. Approved Mirodenafil Mirodenafil may increase the antihypertensive activities of Nitrendipine. Investigational Mitomycin The serum concentration of Mitomycin can be increased when it is combined with Nitrendipine. Approved Mitotane The serum concentration of Nitrendipine can be decreased when it is combined with Mitotane. Approved Mitoxantrone The serum concentration of Mitoxantrone can be increased when it is combined with Nitrendipine. Approved, Investigational Mivacurium Nitrendipine may increase the neuromuscular blocking activities of Mivacurium. Approved Moclobemide Moclobemide may increase the hypotensive activities of Nitrendipine. Approved, Investigational Modafinil The serum concentration of Nitrendipine can be decreased when it is combined with Modafinil. Approved, Investigational Moexipril Moexipril may increase the hypotensive activities of Nitrendipine. Approved Mofebutazone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Mofebutazone. Experimental Molsidomine Molsidomine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Morniflumate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Morniflumate. Approved Morphine The serum concentration of Morphine can be increased when it is combined with Nitrendipine. Approved, Investigational Moxidectin The serum concentration of Moxidectin can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Moxonidine Moxonidine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Muzolimine Nitrendipine may increase the hypotensive activities of Muzolimine. Experimental Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrendipine. Approved, Investigational Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Nitrendipine. Approved, Investigational Nabumetone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nabumetone. Approved Nadolol The serum concentration of Nadolol can be increased when it is combined with Nitrendipine. Approved Nafcillin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nafcillin. Approved, Investigational Naftopidil Nitrendipine may increase the hypotensive activities of Naftopidil. Investigational Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Nitrendipine. Approved Naloxone The metabolism of Nitrendipine can be decreased when combined with Naloxone. Approved, Vet Approved Naproxen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Naproxen. Approved, Vet Approved Nebivolol Nitrendipine may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone The risk or severity of hypotension can be increased when Nefazodone is combined with Nitrendipine. Approved, Withdrawn Nelfinavir The metabolism of Nitrendipine can be decreased when combined with Nelfinavir. Approved Neostigmine The serum concentration of Neostigmine can be increased when it is combined with Nitrendipine. Approved, Vet Approved Nepafenac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nepafenac. Approved, Investigational Nesiritide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nesiritide. Approved, Investigational Netupitant The serum concentration of Nitrendipine can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Nitrendipine can be increased when combined with Nevirapine. Approved Nialamide Nialamide may increase the hypotensive activities of Nitrendipine. Withdrawn Nicardipine The risk or severity of hypotension can be increased when Nicardipine is combined with Nitrendipine. Approved, Investigational Nicergoline The risk or severity of hypotension can be increased when Nicergoline is combined with Nitrendipine. Approved, Investigational Nicorandil Nicorandil may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nifedipine The serum concentration of Nifedipine can be increased when it is combined with Nitrendipine. Approved Nifenazone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nifenazone. Experimental Niflumic Acid The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Niflumic Acid. Approved Niguldipine The risk or severity of hypotension can be increased when Niguldipine is combined with Nitrendipine. Experimental Nilotinib The metabolism of Nitrendipine can be decreased when combined with Nilotinib. Approved, Investigational Nilvadipine Nitrendipine may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimesulide The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nimesulide. Approved, Investigational, Withdrawn Nimodipine Nimodipine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Nitrendipine. Approved Nisoldipine Nisoldipine may increase the hypotensive activities of Nitrendipine. Approved Nitric Oxide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitric Oxide. Approved Nitroaspirin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nitroaspirin. Investigational Nitroglycerin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitroglycerin. Approved, Investigational Nitroprusside Nitrendipine may increase the hypotensive activities of Nitroprusside. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitrous acid. Approved, Investigational Nizatidine The serum concentration of Nizatidine can be increased when it is combined with Nitrendipine. Approved Nortriptyline The risk or severity of hypotension can be increased when Nortriptyline is combined with Nitrendipine. Approved NS-398 The therapeutic efficacy of Nitrendipine can be decreased when used in combination with NS-398. Experimental Obinutuzumab Nitrendipine may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Nitrendipine. Withdrawn Octreotide The serum concentration of Octreotide can be increased when it is combined with Nitrendipine. Approved, Investigational Odanacatib The serum concentration of Odanacatib can be increased when it is combined with Nitrendipine. Investigational Olanzapine The risk or severity of hypotension can be increased when Olanzapine is combined with Nitrendipine. Approved, Investigational Olaparib The metabolism of Nitrendipine can be decreased when combined with Olaparib. Approved Olmesartan Olmesartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Olsalazine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Olsalazine. Approved Omapatrilat Omapatrilat may increase the hypotensive activities of Nitrendipine. Investigational Ombitasvir The serum concentration of Ombitasvir can be increased when it is combined with Nitrendipine. Approved, Investigational Omeprazole The serum concentration of Omeprazole can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved Omoconazole The therapeutic efficacy of Omoconazole can be increased when used in combination with Nitrendipine. Experimental Ondansetron The serum concentration of Ondansetron can be increased when it is combined with Nitrendipine. Approved Oxaprozin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Oxaprozin. Approved Oxiconazole The therapeutic efficacy of Oxiconazole can be increased when used in combination with Nitrendipine. Approved Oxprenolol Nitrendipine may increase the hypotensive activities of Oxprenolol. Approved Oxyphenbutazone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Oxyphenbutazone. Approved, Withdrawn Oxyphenisatin The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Nitrendipine. Investigational, Withdrawn Paclitaxel The serum concentration of Paclitaxel can be increased when it is combined with Nitrendipine. Approved, Vet Approved Palbociclib The serum concentration of Nitrendipine can be increased when it is combined with Palbociclib. Approved, Investigational Paliperidone The risk or severity of hypotension can be increased when Paliperidone is combined with Nitrendipine. Approved Pancuronium Nitrendipine may increase the neuromuscular blocking activities of Pancuronium. Approved Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Nitrendipine. Approved, Investigational Pantoprazole The serum concentration of Pantoprazole can be increased when it is combined with Nitrendipine. Approved Papaverine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Papaverine. Approved, Investigational Parecoxib The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Parecoxib. Approved Pargyline Pargyline may increase the hypotensive activities of Nitrendipine. Approved Paritaprevir The serum concentration of Paritaprevir can be increased when it is combined with Nitrendipine. Approved, Investigational Patent Blue The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Patent Blue. Approved Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Nitrendipine. Approved Penbutolol Nitrendipine may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentaerithrityl The therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Nitrendipine. Experimental Pentazocine The serum concentration of Pentazocine can be increased when it is combined with Nitrendipine. Approved, Vet Approved Pentobarbital Pentobarbital may increase the hypotensive activities of Nitrendipine. Approved, Investigational, Vet Approved Pentolinium Nitrendipine may increase the hypotensive activities of Pentolinium. Approved Perindopril Perindopril may increase the hypotensive activities of Nitrendipine. Approved Perindoprilat Nitrendipine may increase the hypotensive activities of Perindoprilat. Experimental Phenelzine Phenelzine may increase the hypotensive activities of Nitrendipine. Approved Pheniprazine Pheniprazine may increase the hypotensive activities of Nitrendipine. Withdrawn Phenobarbital Phenobarbital may increase the hypotensive activities of Nitrendipine. Approved, Investigational Phenolphthalein The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Nitrendipine. Approved, Withdrawn Phenothiazine The serum concentration of Phenothiazine can be increased when it is combined with Nitrendipine. Vet Approved Phenoxybenzamine The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Nitrendipine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Nitrendipine. Withdrawn Phentolamine The risk or severity of hypotension can be increased when Phentolamine is combined with Nitrendipine. Approved Phenylbutazone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Phenylbutazone. Approved, Vet Approved Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Nitrendipine. Approved, Vet Approved Pibrentasvir The serum concentration of Pibrentasvir can be increased when it is combined with Nitrendipine. Approved, Investigational Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nitrendipine. Approved Pinacidil Pinacidil may increase the hypotensive activities of Nitrendipine. Approved Pindolol Nitrendipine may increase the hypotensive activities of Pindolol. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Pipamperone. Approved, Investigational Pipecuronium Nitrendipine may increase the neuromuscular blocking activities of Pipecuronium. Approved Pirlindole Pirlindole may increase the hypotensive activities of Nitrendipine. Approved Piroxicam The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Piroxicam. Approved, Investigational Pirprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Pirprofen. Experimental Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Nitrendipine. Approved Pitolisant The serum concentration of Nitrendipine can be decreased when it is combined with Pitolisant. Approved, Investigational Pivhydrazine Pivhydrazine may increase the hypotensive activities of Nitrendipine. Withdrawn Pizotifen The risk or severity of hypotension can be increased when Pizotifen is combined with Nitrendipine. Approved Plantago seed The therapeutic efficacy of Plantago seed can be decreased when used in combination with Nitrendipine. Approved, Investigational Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Nitrendipine. Approved, Investigational Polycarbophil The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Nitrendipine. Approved Polyethylene glycol The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nitrendipine. Approved, Vet Approved Polythiazide Nitrendipine may increase the hypotensive activities of Polythiazide. Approved Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Nitrendipine. Approved Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Nitrendipine. Approved, Investigational Posaconazole The metabolism of Nitrendipine can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Potassium acetate The therapeutic efficacy of Potassium acetate can be decreased when used in combination with Nitrendipine. Approved, Investigational Practolol Nitrendipine may increase the hypotensive activities of Practolol. Approved Pramipexole The risk or severity of adverse effects can be increased when Nitrendipine is combined with Pramipexole. Approved, Investigational Pranoprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Pranoprofen. Experimental, Investigational Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Nitrendipine. Approved Prazosin The risk or severity of hypotension can be increased when Prazosin is combined with Nitrendipine. Approved Prednisolone The serum concentration of Prednisolone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Prednisone The serum concentration of Prednisone can be increased when it is combined with Nitrendipine. Approved, Vet Approved Primidone Primidone may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Proglumetacin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Proglumetacin. Experimental Promazine The risk or severity of hypotension can be increased when Promazine is combined with Nitrendipine. Approved, Vet Approved Propacetamol The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Propacetamol. Approved, Investigational Propericiazine The risk or severity of hypotension can be increased when Propericiazine is combined with Nitrendipine. Approved, Investigational Propiomazine The risk or severity of hypotension can be increased when Propiomazine is combined with Nitrendipine. Approved Propiverine The risk or severity of hypotension can be increased when Propiverine is combined with Nitrendipine. Approved, Investigational Propofol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Propofol. Approved, Investigational, Vet Approved Propranolol The serum concentration of Propranolol can be increased when it is combined with Nitrendipine. Approved, Investigational Propyphenazone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Propyphenazone. Experimental Proquazone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Proquazone. Experimental Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Nitrendipine. Approved Quetiapine The risk or severity of hypotension can be increased when Quetiapine is combined with Nitrendipine. Approved Quinapril Quinapril may increase the hypotensive activities of Nitrendipine. Approved, Investigational Quinaprilat Nitrendipine may increase the hypotensive activities of Quinaprilat. Experimental Quinidine The risk or severity of hypotension can be increased when Quinidine is combined with Nitrendipine. Approved, Investigational Quinine The metabolism of Nitrendipine can be increased when combined with Quinine. Approved Ramipril Ramipril may increase the hypotensive activities of Nitrendipine. Approved Ramiprilat Nitrendipine may increase the hypotensive activities of Ramiprilat. Experimental Ranitidine The serum concentration of Ranitidine can be increased when it is combined with Nitrendipine. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Nitrendipine. Approved, Investigational Rapacuronium Nitrendipine may increase the neuromuscular blocking activities of Rapacuronium. Withdrawn Rasagiline Rasagiline may increase the hypotensive activities of Nitrendipine. Approved Ravuconazole The therapeutic efficacy of Ravuconazole can be increased when used in combination with Nitrendipine. Investigational Regorafenib The serum concentration of Regorafenib can be increased when it is combined with Nitrendipine. Approved Remifentanil The risk or severity of adverse effects can be increased when Nitrendipine is combined with Remifentanil. Approved Remikiren Remikiren may increase the hypotensive activities of Nitrendipine. Approved Rescinnamine Nitrendipine may increase the hypotensive activities of Rescinnamine. Approved Reserpine The serum concentration of Reserpine can be increased when it is combined with Nitrendipine. Approved, Investigational Rhodamine 6G The serum concentration of Rhodamine 6G can be increased when it is combined with Nitrendipine. Experimental Rifampicin The metabolism of Nitrendipine can be increased when combined with Rifampicin. Approved Rifamycin The metabolism of Nitrendipine can be increased when combined with Rifamycin. Investigational Rifapentine The metabolism of Nitrendipine can be increased when combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Nitrendipine. Approved, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Rimexolone The metabolism of Nitrendipine can be increased when combined with Rimexolone. Approved Riociguat Nitrendipine may increase the hypotensive activities of Riociguat. Approved Risperidone Nitrendipine may increase the hypotensive activities of Risperidone. Approved, Investigational Ritonavir The metabolism of Nitrendipine can be decreased when combined with Ritonavir. Approved, Investigational Rituximab Nitrendipine may increase the hypotensive activities of Rituximab. Approved Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Nitrendipine. Approved Robenacoxib The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Robenacoxib. Experimental, Vet Approved Rocuronium Nitrendipine may increase the neuromuscular blocking activities of Rocuronium. Approved Rofecoxib The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Rofecoxib. Approved, Investigational, Withdrawn Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Nitrendipine. Approved, Investigational Ropinirole The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropivacaine. Approved Rotigotine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Rotigotine. Approved Rucaparib The serum concentration of Rucaparib can be increased when it is combined with Nitrendipine. Approved, Investigational Sacubitril The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sacubitril. Approved Safinamide Safinamide may increase the hypotensive activities of Nitrendipine. Approved, Investigational Safrazine Safrazine may increase the hypotensive activities of Nitrendipine. Withdrawn Salicylamide The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Salicylamide. Approved Salicylic acid The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Salicylic acid. Approved, Investigational, Vet Approved Salsalate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Salsalate. Approved Saprisartan Nitrendipine may increase the hypotensive activities of Saprisartan. Experimental Saquinavir The metabolism of Nitrendipine can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Sarilumab. Approved, Investigational SC-236 The therapeutic efficacy of Nitrendipine can be decreased when used in combination with SC-236. Experimental, Investigational Secobarbital Secobarbital may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Nitrendipine. Approved, Investigational, Vet Approved Selexipag The serum concentration of Selexipag can be increased when it is combined with Nitrendipine. Approved Sennosides The therapeutic efficacy of Sennosides can be decreased when used in combination with Nitrendipine. Approved Sertaconazole The therapeutic efficacy of Sertaconazole can be increased when used in combination with Nitrendipine. Approved, Investigational Sevoflurane The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sevoflurane. Approved, Vet Approved Sildenafil Sildenafil may increase the antihypertensive activities of Nitrendipine. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Nitrendipine. Approved Siltuximab The serum concentration of Nitrendipine can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Nitrendipine can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Nitrendipine. Approved Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Nitrendipine. Approved, Investigational Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Nitrendipine. Approved, Investigational Sitaxentan Nitrendipine may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sodium phosphate, monobasic The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Nitrendipine. Approved Sodium sulfate The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Nitrendipine. Approved, Vet Approved Sodium tartrate The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Nitrendipine. Approved Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Nitrendipine. Approved Somatostatin The serum concentration of Somatostatin can be increased when it is combined with Nitrendipine. Approved, Investigational Sorafenib The serum concentration of Sorafenib can be increased when it is combined with Nitrendipine. Approved, Investigational Sorbitol The therapeutic efficacy of Sorbitol can be decreased when used in combination with Nitrendipine. Approved Sotalol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sotalol. Approved Sparfloxacin The serum concentration of Sparfloxacin can be increased when it is combined with Nitrendipine. Approved, Investigational Sphingosine The serum concentration of Sphingosine can be increased when it is combined with Nitrendipine. Experimental Spirapril Nitrendipine may increase the hypotensive activities of Spirapril. Approved Spironolactone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Spironolactone. Approved St. John's Wort The serum concentration of Nitrendipine can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stanolone The serum concentration of Stanolone can be increased when it is combined with Nitrendipine. Illicit, Investigational Stanolone acetate The serum concentration of Stanolone acetate can be increased when it is combined with Nitrendipine. Experimental Stiripentol The serum concentration of Nitrendipine can be increased when it is combined with Stiripentol. Approved Streptokinase The risk or severity of adverse effects can be increased when Nitrendipine is combined with Streptokinase. Approved, Investigational Sufentanil The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil. Approved, Investigational Sulconazole The therapeutic efficacy of Sulconazole can be increased when used in combination with Nitrendipine. Approved Sulfasalazine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Sulfasalazine. Approved Sulindac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Sulindac. Approved, Investigational Sumatriptan The serum concentration of Sumatriptan can be increased when it is combined with Nitrendipine. Approved, Investigational Sunitinib The serum concentration of Sunitinib can be increased when it is combined with Nitrendipine. Approved, Investigational Suprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Suprofen. Approved, Withdrawn Suxibuzone The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Suxibuzone. Experimental Tacrine The serum concentration of Tacrine can be increased when it is combined with Nitrendipine. Investigational, Withdrawn Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Nitrendipine. Approved, Investigational Tadalafil Tadalafil may increase the antihypertensive activities of Nitrendipine. Approved, Investigational Talinolol The serum concentration of Talinolol can be increased when it is combined with Nitrendipine. Investigational Talniflumate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Talniflumate. Approved Tamoxifen The serum concentration of Tamoxifen can be increased when it is combined with Nitrendipine. Approved Tamsulosin The risk or severity of hypotension can be increased when Tamsulosin is combined with Nitrendipine. Approved, Investigational Taurocholic Acid The serum concentration of Taurocholic Acid can be increased when it is combined with Nitrendipine. Experimental Technetium Tc-99m sestamibi The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nitrendipine. Approved, Investigational Tegaserod The therapeutic efficacy of Tegaserod can be decreased when used in combination with Nitrendipine. Approved, Investigational, Withdrawn Telaprevir The metabolism of Nitrendipine can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Nitrendipine can be decreased when combined with Telithromycin. Approved Telmisartan Telmisartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Temocapril Nitrendipine may increase the hypotensive activities of Temocapril. Experimental, Investigational Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Nitrendipine. Approved Tenidap The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tenidap. Experimental Teniposide The serum concentration of Teniposide can be increased when it is combined with Nitrendipine. Approved Tenoxicam The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tenoxicam. Approved Tepoxalin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tepoxalin. Vet Approved Terazosin The risk or severity of hypotension can be increased when Terazosin is combined with Nitrendipine. Approved Terconazole The therapeutic efficacy of Terconazole can be increased when used in combination with Nitrendipine. Approved Terfenadine The serum concentration of Terfenadine can be increased when it is combined with Nitrendipine. Approved, Withdrawn Testosterone propionate The serum concentration of Testosterone propionate can be increased when it is combined with Nitrendipine. Approved, Investigational, Vet Approved, Withdrawn Tetracycline The serum concentration of Tetracycline can be increased when it is combined with Nitrendipine. Approved, Vet Approved Tetrahydropalmatine Nitrendipine may increase the hypotensive activities of Tetrahydropalmatine. Investigational Thalidomide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Thalidomide. Approved, Investigational, Withdrawn Theophylline Theophylline may increase the antihypertensive activities of Nitrendipine. Approved Thiamylal Thiamylal may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Thiopental Thiopental may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Thioproperazine The risk or severity of hypotension can be increased when Thioproperazine is combined with Nitrendipine. Approved Thioridazine The risk or severity of hypotension can be increased when Thioridazine is combined with Nitrendipine. Approved, Withdrawn Tiaprofenic acid The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tiaprofenic acid. Approved Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Nitrendipine. Approved Ticrynafen Nitrendipine may increase the hypotensive activities of Ticrynafen. Withdrawn Timolol The serum concentration of Timolol can be increased when it is combined with Nitrendipine. Approved Tinoridine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tinoridine. Investigational Tioconazole The therapeutic efficacy of Tioconazole can be increased when used in combination with Nitrendipine. Approved Tipranavir The metabolism of Nitrendipine can be decreased when combined with Tipranavir. Approved, Investigational Tizanidine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tizanidine. Approved, Investigational Tocilizumab The serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab. Approved Tocopherylquinone Nitrendipine may increase the hypotensive activities of Tocopherylquinone. Experimental, Investigational Tolazoline The risk or severity of hypotension can be increased when Tolazoline is combined with Nitrendipine. Approved, Vet Approved Tolcapone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tolcapone. Approved, Withdrawn Tolfenamic Acid The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tolfenamic Acid. Approved, Investigational Tolmetin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tolmetin. Approved Tolonidine Nitrendipine may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Nitrendipine. Approved Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Nitrendipine. Approved Topiramate The serum concentration of Topiramate can be increased when it is combined with Nitrendipine. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Nitrendipine. Approved, Investigational Torasemide Torasemide may increase the hypotensive activities of Nitrendipine. Approved Trandolapril Trandolapril may increase the hypotensive activities of Nitrendipine. Approved Tranylcypromine Tranylcypromine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Trastuzumab emtansine The serum concentration of Trastuzumab emtansine can be increased when it is combined with Nitrendipine. Approved, Investigational Travoprost Travoprost may increase the hypotensive activities of Nitrendipine. Approved Trazodone The risk or severity of hypotension can be increased when Trazodone is combined with Nitrendipine. Approved, Investigational Treprostinil Treprostinil may increase the hypotensive activities of Nitrendipine. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tretinoin. Approved, Investigational, Nutraceutical Triamterene The risk or severity of adverse effects can be increased when Nitrendipine is combined with Triamterene. Approved Trichlormethiazide Trichlormethiazide may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Trifluoperazine The risk or severity of hypotension can be increased when Trifluoperazine is combined with Nitrendipine. Approved, Investigational Trimazosin The risk or severity of hypotension can be increased when Trimazosin is combined with Nitrendipine. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Trimipramine The risk or severity of hypotension can be increased when Trimipramine is combined with Nitrendipine. Approved Trolamine salicylate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Trolamine salicylate. Approved Troleandomycin The metabolism of Nitrendipine can be decreased when combined with Troleandomycin. Approved Tubocurarine Nitrendipine may increase the neuromuscular blocking activities of Tubocurarine. Approved Ubidecarenone The serum concentration of Ubidecarenone can be increased when it is combined with Nitrendipine. Approved, Investigational, Nutraceutical Udenafil Udenafil may increase the antihypertensive activities of Nitrendipine. Approved, Investigational Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Nitrendipine. Approved Unoprostone Nitrendipine may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil The risk or severity of hypotension can be increased when Urapidil is combined with Nitrendipine. Investigational Ursodeoxycholic acid Ursodeoxycholic acid can cause a decrease in the absorption of Nitrendipine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Valdecoxib The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Valdecoxib. Approved, Investigational, Withdrawn Valinomycin The serum concentration of Valinomycin can be increased when it is combined with Nitrendipine. Experimental Valsartan Valsartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Valspodar The serum concentration of Valspodar can be increased when it is combined with Nitrendipine. Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Nitrendipine. Approved Vecuronium Nitrendipine may increase the neuromuscular blocking activities of Vecuronium. Approved Velpatasvir The serum concentration of Velpatasvir can be increased when it is combined with Nitrendipine. Approved, Investigational Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nitrendipine. Approved Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Nitrendipine. Approved, Investigational Venlafaxine The serum concentration of Venlafaxine can be increased when it is combined with Nitrendipine. Approved Verapamil The risk or severity of hypotension can be increased when Verapamil is combined with Nitrendipine. Approved Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Nitrendipine. Approved Vincamine Nitrendipine may increase the hypotensive activities of Vincamine. Experimental Vincristine The excretion of Vincristine can be decreased when combined with Nitrendipine. Approved, Investigational Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Nitrendipine. Approved, Investigational Vinorelbine The serum concentration of Vinorelbine can be increased when it is combined with Nitrendipine. Approved, Investigational Vismodegib The serum concentration of Vismodegib can be increased when it is combined with Nitrendipine. Approved, Investigational Voriconazole The metabolism of Nitrendipine can be decreased when combined with Voriconazole. Approved, Investigational Voxilaprevir The serum concentration of Voxilaprevir can be increased when it is combined with Nitrendipine. Approved, Investigational Xipamide Nitrendipine may increase the hypotensive activities of Xipamide. Experimental Yohimbine Yohimbine may decrease the antihypertensive activities of Nitrendipine. Approved, Investigational, Vet Approved Zaltoprofen The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Zaltoprofen. Approved, Investigational Zidovudine The serum concentration of Zidovudine can be increased when it is combined with Nitrendipine. Approved Ziprasidone The risk or severity of hypotension can be increased when Ziprasidone is combined with Nitrendipine. Approved Zofenopril Nitrendipine may increase the hypotensive activities of Zofenopril. Experimental Zomepirac The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Zomepirac. Withdrawn Zuclopenthixol The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nitrendipine. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Wolfgang Schmidt, Bernhard Streuff, Manfred Winter, "Preparation of solid medicament formulation containing nitrendipine." U.S. Patent US4724141, issued April, 1980.
US4724141- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015187
- KEGG Drug
- D00629
- KEGG Compound
- C07713
- PubChem Compound
- 4507
- PubChem Substance
- 46508817
- ChemSpider
- 4351
- BindingDB
- 50012016
- ChEBI
- 7582
- ChEMBL
- CHEMBL475534
- Therapeutic Targets Database
- DAP001263
- PharmGKB
- PA146096020
- IUPHAR
- 2334
- Guide to Pharmacology
- GtP Drug Page
- Wikipedia
- Nitrendipine
- ATC Codes
- C08CA08 — Nitrendipine
- C08CA — Dihydropyridine derivatives
- C08C — SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
- C08 — CALCIUM CHANNEL BLOCKERS
- C — CARDIOVASCULAR SYSTEM
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Unknown Status Treatment High Blood Pressure (Hypertension) 1 4 Withdrawn Treatment Chronic Kidney Disease (CKD) / High Blood Pressure (Hypertension) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 156-160 °C Not Available water solubility Insoluble Not Available logP 2.88 MASUMATO,K ET AL. (1995) Caco2 permeability -4.77 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 0.0142 mg/mL ALOGPS logP 3.21 ALOGPS logP 2.17 ChemAxon logS -4.4 ALOGPS pKa (Strongest Basic) 5.43 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 110.45 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 96.91 m3·mol-1 ChemAxon Polarizability 36.25 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9536 Blood Brain Barrier - 0.9549 Caco-2 permeable + 0.7853 P-glycoprotein substrate Substrate 0.5265 P-glycoprotein inhibitor I Inhibitor 0.8564 P-glycoprotein inhibitor II Inhibitor 0.8313 Renal organic cation transporter Non-inhibitor 0.8984 CYP450 2C9 substrate Non-substrate 0.8212 CYP450 2D6 substrate Non-substrate 0.8931 CYP450 3A4 substrate Substrate 0.7266 CYP450 1A2 substrate Inhibitor 0.9107 CYP450 2C9 inhibitor Inhibitor 0.8949 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Inhibitor 0.8993 CYP450 3A4 inhibitor Inhibitor 0.8037 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.9247 Ames test Non AMES toxic 0.7334 Carcinogenicity Non-carcinogens 0.5186 Biodegradation Not ready biodegradable 0.9581 Rat acute toxicity 2.3810 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8131 hERG inhibition (predictor II) Non-inhibitor 0.9094
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-QFT , negative LC-MS/MS splash10-0ab9-2539000000-3d9a9111a145f234fc24 MS/MS Spectrum - , positive LC-MS/MS splash10-016r-0159000000-7b0ccf9fb639868092f0 LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-016r-0159000000-4e10a6643ba97ab23a0f
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Hydropyridines
- Direct Parent
- Dihydropyridinecarboxylic acids and derivatives
- Alternative Parents
- Nitrobenzenes / Nitroaromatic compounds / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Enamines show 6 more
- Substituents
- Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Methyl ester / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Vinylogous amide show 23 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- C-nitro compound, ethyl ester, diester, dihydropyridine (CHEBI:7582)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1C
- Uniprot ID
- Q13936
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit alpha-1C
- Molecular Weight
- 248974.1 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
- Gene Name
- CACNA2D1
- Uniprot ID
- P54289
- Uniprot Name
- Voltage-dependent calcium channel subunit alpha-2/delta-1
- Molecular Weight
- 124566.93 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
- Gene Name
- CACNB2
- Uniprot ID
- Q08289
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit beta-2
- Molecular Weight
- 73579.925 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
- Gene Name
- CACNG1
- Uniprot ID
- Q06432
- Uniprot Name
- Voltage-dependent calcium channel gamma-1 subunit
- Molecular Weight
- 25028.105 Da
References
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity involved sa node cell action potential
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1D
- Uniprot ID
- Q01668
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit alpha-1D
- Molecular Weight
- 245138.75 Da
References
- Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1S
- Uniprot ID
- Q13698
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit alpha-1S
- Molecular Weight
- 212348.1 Da
References
- Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
- Gene Name
- CACNA2D2
- Uniprot ID
- Q9NY47
- Uniprot Name
- Voltage-dependent calcium channel subunit alpha-2/delta-2
- Molecular Weight
- 129816.095 Da
References
- Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Scaffold protein binding
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1H
- Uniprot ID
- O95180
- Uniprot Name
- Voltage-dependent T-type calcium channel subunit alpha-1H
- Molecular Weight
- 259160.2 Da
References
- Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A7
- Uniprot ID
- P24462
- Uniprot Name
- Cytochrome P450 3A7
- Molecular Weight
- 57525.03 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
- Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Transporter activity
- Specific Function
- Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
- Gene Name
- ABCB11
- Uniprot ID
- O95342
- Uniprot Name
- Bile salt export pump
- Molecular Weight
- 146405.83 Da
References
- Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]
Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:48